Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO for the Treatment of Dry Eye Disease

First company in the world to offer preclinical drug tests for children with cancer

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

"G7 Cancer": Seven leading organizations strengthen their coordination

CEBR appoints new President and Vice-president at its Annual Meeting 2023

Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline

BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim

New research building for the engineering of life-inspired molecular systems

Novaliq announces publication of second pivotal phase 3 trial data on CyclASol®

Germany Life Science Trend Analysis 2023

Ascendis Pharma’s Initial Dose Escalation Results Accepted for Online Publication at ASCO 2023

Heidelberg Pharma Presents New Preclinical Data at AACR Annual Meeting 2023

BioMed X and Merck Expand Collaboration

German Biotechnology Days in Wiesbaden - the magic is back

Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 %

AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28

NOV03 Consistently Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease

State of Baden-Württemberg agrees on close association model for the two university hospitals

Research support along the investment cycle